Cefixime
- Generic Name
- Cefixime
- Brand Names
- Suprax
- Drug Type
- Small Molecule
- Chemical Formula
- C16H15N5O7S2
- CAS Number
- 79350-37-1
- Unique Ingredient Identifier
- XZ7BG04GJX
- Background
Cefixime, an antibiotic, is a third-generation cephalosporin like ceftriaxone and cefotaxime. Cefixime is highly stable in the presence of beta-lactamase enzymes. As a result, many organisms resistant to penicillins and some cephalosporins due to the presence of beta-lactamases, may be susceptible to cefixime. The antibacterial effect of cefixime results fro...
- Indication
For use in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: (1) uncomplicated urinary tract infections caused by Escherichia coli and Proteus mirabilis, (2) otitis media caused by Haemophilus influenzae (beta-lactamase positive and negative strains), Moraxella catarrhalis (most of which are beta-l...
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis caused by Streptococcus Pneumoniae, Acute Exacerbations of Chronic Bronchitis caused by Haemophilus Influenzae, Bacterial Sinusitis, Community Acquired Pneumonia (CAP), Gonorrhea of anus, Lyme Disease, Salmonella Infections, Shigella Infection, Streptococcal Pharyngitis, Tonsillitis streptococcal, Uncomplicated Urinary Tract Infections, Bacterial otitis media, Bacterial rhinosinusitis, Disease caused by Salmonella typhi, Uncomplicated Gonorrhea
- Associated Therapies
- -
Empiric Therapy of Mucopurulent Cervicitis (MPC)
- Conditions
- Interventions
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2014-12-24
- Target Recruit Count
- 87
- Registration Number
- NCT01072136
- Locations
- 🇺🇸
University of Mississippi - Infectious Diseases, Jackson, Mississippi, United States
🇺🇸Harbor UCLA Medical Center - OBGYN - General Gynecology and Women's Health, Torrance, California, United States
🇺🇸Louisiana Stte University - Health Sciences Center - Medicine, New Orleans, Louisiana, United States
A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 13
- Registration Number
- NCT00786669
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 30
- Registration Number
- NCT00093353
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
VNP20009 in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Therapy
- Conditions
- First Posted Date
- 2004-02-25
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Vion Pharmaceuticals
- Registration Number
- NCT00004216
- Locations
- 🇺🇸
Mary Crowley Medical Research Center, Dallas, Texas, United States
🇺🇸Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.